VenoVision
Non-invasive, easy-to-use advanced cardiac and hemodynamic monitoring.
StartupVenoVision is a Jerusalem-based startup in the Health Tech & Life Sciences sector, established in 2022. Non-invasive, easy-to-use advanced cardiac and hemodynamic monitoring.. The company has raised a total of $187.5K across 5 funding rounds, currently at the Pre-Seed stage. VenoVision was founded by Nadav Lankin, Dr. Tal Hasin, Prof. Yaakov Nahmias, Jonathan Maron. The company has 1-10 employees. Core technologies: Sensing, Biometrics, Infrared, Artificial Intelligence, Computer Vision, Machine Learning, Image Recognition.
With $187.5K in total funding, VenoVision is a Pre-Seed-stage company operating in Health Tech & Life Sciences. The company follows a B2B business model. Product stage: Clinical Trial. The company holds 1 patent.
- StagePre-Seed
- ProductClinical Trial
- ModelB2B
- Employees1-10
- HQJerusalem
- DistrictJerusalem District
- Last Round$7.5K
Nadav LankinCo-founder
Dr. Tal HasinCo-founder
Prof. Yaakov NahmiasCo-founder
Jonathan MaronCo-founder
7 articles covered by sources including masschallenge.org,
www.openpr.com,
hsrlce.utoronto.ca,
patents.google.com,
innovex.computex.biz.
What does VenoVision do?
VenoVision provides the missing non-invasive advanced cardiac monitoring needed to improve the lives of millions of heart failure and at-risk patients. VenoVision brings the power of ICU cardiac monitoring to lower resource settings, giving medical teams the hemodynamic data needed to adjust therapy in time to reduce ICU admissions and hospitalizations. VenoVision is a low cost, easy-to-use, thermal imaging-based hemodynamic monitoring device and platform for the entire continuum of care - inpatient, outpatient and home settings. It uniquely overcomes the challenges of monitoring obese patients. The company is focused on driving down the billions of dollars currently spent on preventable deterioration and rehospitalizations. It has completed a proof-of-concept clinical trial, designed a prototype, and patented its technology. VenoVision was conceptualized in the Hebrew University of Jerusalem's BioDesign program, was a MassChallenge Israel 2021 Finalist, and is a Health Wildcatters Dallas accelerator (Dallas, USA) 2022 portfolio company. VenoVision won "most innovative" award at M2D2 Impact 2023.
How much funding has VenoVision raised?
VenoVision has raised $187.5K in total funding across 5 rounds. The company is currently at the Pre-Seed stage.
Who founded VenoVision?
VenoVision was founded in 2022 by Nadav Lankin (Co-founder), Dr. Tal Hasin (Co-founder), Prof. Yaakov Nahmias (Co-founder), Jonathan Maron (Co-founder).
What sector is VenoVision in?
VenoVision operates in Health Tech & Life Sciences, Digital Healthcare, Patient Remote Monitoring, Medical Devices, Medical Monitors, with core technologies in Sensing, Biometrics, Infrared, Artificial Intelligence, Computer Vision, Machine Learning, Image Recognition. Target customers: Healthcare & Life Sciences, Medical Devices Industry, Medical Equipment, Healthcare, Providers.
Where is VenoVision located?
VenoVision is based in Jerusalem, Israel, Jerusalem District. The company also has offices abroad.